Takeda (TYO: 4502), a leading Japanese pharmaceutical company, has entered into an agreement with India-based Biological E (BE) with the aim of increasing production capacity for its dengue tetravalent vaccine, QDenga. This strategic partnership is part of Takeda’s broader plan to manufacture 100 million doses of the vaccine annually. QDenga, which was launched last year to the private markets in Argentina, Brazil, Europe, Indonesia, and Thailand, is now poised to expand its reach to the public sectors in Argentina and Brazil.
According to the terms of the agreement, BE has committed to producing up to 50 million doses per year in a multi-dose vial (MDV) presentation. This packaging format is designed to reduce packaging and storage costs, which is particularly beneficial for government procurement programs. The partners aim to target these cost-sensitive programs by 2030, thereby increasing the accessibility of the vaccine to a broader population.
This collaboration between Takeda and BE highlights the growing focus on global health initiatives and the need for affordable and efficient vaccination programs, especially in regions where dengue fever is a significant public health concern.- Flcube.com
